27th Oct 2010
Successful investing starts with a smart watchlist.
Investors should give Bristol-Myers a pass on revenue for a few quarters,
but if the pipeline can't produce winners soon, the drop off the patent
cliff is going to hurt.
Read Full Article at Motley Fool